Department of Histology and Embryology, Harbin Medical University, Heilongjiang, 150081, China; Department of Anatomy, Harbin Medical University, Heilongjiang, 150081, China.
Department of Histology and Embryology, Harbin Medical University, Heilongjiang, 150081, China.
Cytokine Growth Factor Rev. 2020 Apr;52:1-14. doi: 10.1016/j.cytogfr.2020.02.002. Epub 2020 Feb 5.
Immune checkpoint inhibitors (ICIs) and immunotherapy have proven to be a transformative therapy for many forms of cancer treatment. While many antibodies targeting the PD-1, PD-L1, and CTLA-4 pathways have been approved for clinical use by the FDA, it is clear that a single ICI is not sufficient to eradicate disease. ICI combination strategies are being extensively investigated to advance cancer treatment to next curative stage. Among the immune checkpoint inhibitors being actively investigated, the potential of VISTA (V-domain Ig suppressor of T cell activation), a unique B7 family member that functions as both ligand and receptor, is being actively pursued. This article summarizes the expression and immunomodulatory effects of VISTA in autoimmune diseases and cancer, and assesses its potential as an additional component of immune checkpoint cancer therapy.
免疫检查点抑制剂（ICIs）和免疫疗法已被证明是治疗多种癌症的变革性疗法。虽然许多针对 PD-1、PD-L1 和 CTLA-4 通路的抗体已被 FDA 批准用于临床应用，但显然单一的 ICI 不足以消除疾病。ICI 联合策略正在被广泛研究，以将癌症治疗推进到下一个治愈阶段。在正在积极研究的免疫检查点抑制剂中，VISTA（T 细胞活化的 V 域免疫球蛋白抑制剂）作为配体和受体发挥作用的独特 B7 家族成员的潜力正在被积极探索。本文总结了 VISTA 在自身免疫性疾病和癌症中的表达和免疫调节作用，并评估了其作为免疫检查点癌症治疗的附加成分的潜力。
